88. 慢性血栓塞栓性肺高血圧症 Chronic thromboembolic pulmonary hypertension Clinical trials / Disease details
臨床試験数 : 159 / 薬物数 : 118 - (DrugBank : 23) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 53
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-006441-10-DE (EUCTR) | 27/05/2010 | 28/01/2010 | Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | Trade Name: Remodulin 1mg/ml 20ml Other descriptive name: TREPROSTINIL SODIUM Trade Name: Remodulin 2.5mg/ml 20ml Other descriptive name: TREPROSTINIL SODIUM Trade Name: Remodulin 5mg/ml 20ml Other descriptive name: TREPROSTINIL SODIUM Trade Name: Remodulin 10mg/ml 20ml Other descriptive name: TREPROSTINIL SODIUM | MRN-Medical Research Network GmbH | NULL | Not Recruiting | Female: yes Male: yes | 100 | Czech Republic;Germany;Austria | |||
| 2 | EUCTR2008-006441-10-CZ (EUCTR) | 15/10/2009 | 24/07/2009 | Study to evaluate the efficacy and safety of Treprostinil which will becontinuously administered under the skin by patients with inoperableChronic Thromboembolic Pulmonary Hypertension. | A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH II) | Patients with Severe inoperable Chronic Thromboembolic Pulmonary Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: Treprostinil Sodium INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM Product Name: Treprostinil Sodium INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM | SCIPHARM SáRL | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 3 | Czech Republic;Slovakia;Poland;Austria;Germany | ||
| 3 | EUCTR2008-006441-10-SK (EUCTR) | 31/08/2009 | 09/09/2009 | Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | Trade Name: Remodulin (R) Trade Name: Remodulin (R) | MRN-Medical Research Network GmbH | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 3 | Czech Republic;Slovakia;Austria;Germany | ||
| 4 | EUCTR2008-006441-10-AT (EUCTR) | 03/06/2009 | 09/12/2008 | Study to evaluate the efficacy and safety of Treprostinil which will be continuously administered under the skin by patients with inoperable Chronic Thromboembolic Pulmonary Hypertension. | A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH II) | Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: Treprostinil Sodium INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM Product Name: Treprostinil Sodium INN or Proposed INN: Treprostinil Other descriptive name: TREPROSTINIL SODIUM | SCIPHARM SáRL | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Czech Republic;Slovakia;Poland;Austria;Germany | ||
| 5 | NCT01416636 (ClinicalTrials.gov) | March 2009 | 12/8/2011 | Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH) | A Double Blind Controlled Clinical Study to Investigate the Efficacy and Tolerability of Subcutaneous Treprostinil Sodium in Patients With Severe Non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH) | Non-operable Chronic Thromboembolic Pulmonary Hypertension | Drug: Treprostinil sodium | SciPharm SàRL | NULL | Active, not recruiting | 18 Years | 100 Years | All | 105 | Phase 3 | Austria;Czechia;Germany;Poland;Czech Republic |